AMX0035
Phase 3Small molecule
AMX0035 is one of 48 small molecule programs targeting Wolfram syndrome. It is currently in Phase 3.
3
Indications
11
Total Trials
4
Active Trials
47
Competitors
Pipeline
Status by Indication[3][1]
Indication
Competition
Competitive Landscape
55 competitors in Amyotrophic Lateral Sclerosis
#DrugCompanyPhaseTrials
1Nourianz
Kyowa Kirin Co., Ltd.Approved
Vimpat
UCBApproved
Enablex
AbbVieApproved
Bosulif
PPrism Pharmaceuticals
Approved
Quinidine Gluconate
WWyeth-Lederle Vaccines
Approved
Transderm Scop
BBaxter Healthcare Corporation
Approved
Rocephin
CConrado Roberto Hoffmann Filho
Approved
Mirapex
Boehringer IngelheimApproved
Avodart
Akero TherapeuticsApproved
Rapamune
PPrism Pharmaceuticals
Approved
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Timeline
Expected Milestones
Clinical
Trials by Indication[1]
Amyotrophic Lateral Sclerosis3 trials
ALS3 trials
Alzheimer's Disease1 trial
Sources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for AMX0035. EMBL-EBI & Wellcome Sanger Institute.
- [4]
Details
Drug Info
Quick Facts
- Modality
- Small molecule[2]
- Highest Phase
- Phase 3[1]
- Company
- AAmylyx Pharmaceuticals Inc.